Alumis Q3 net loss $110.8M; cash $377.7M; Phase 3 psoriasis data expected Q1 2026

ALUMIS INC.

2025-Q3 EPS reported -$1.92 revenue$22,121,000

Net loss of $110.8M for Q3 2025 vs. $93.1M in Q3 2024; R&D expenses rose to $97.8M from $87.8M.
Cash, cash equivalents and marketable securities totaled $377.7M as of September 30, 2025.
Topline Phase 3 ONWARD data for envudeucitinib in plaque psoriasis expected early Q1 2026; Phase 2b SLE data in Q3 2026.
Collaboration revenue of $2.1M from Kaken Pharmaceutical in Q3 2025.
Company expects existing cash to fund pipeline and operations into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.